

Oxytocin-augmented group psychotherapy for patients with schizophrenia spectrum disorders



PRINCIPLE INVESTIGATORS:

Dr. Marco Zierhut, PD Dr. Dr. Kerem Böge, Prof. Dr. Stephan Ripke
Charité



SUMMARY

Negative symptoms (NS) in patients with schizophrenia spectrum disorder (SSD), such as reduced emotional expression and social withdrawal, remain a challenge and limit the efficacy of existing treatments. This project aims to develop and optimize a combination therapy of Mindfulness-Based Group Therapy and oxytocin administration (OXYMIND) to improve the overall well-being and quality of life for patients.

We will perform an interventional study and investigate potential mechanism of action to improve therapeutic effects.

PROJECT GOALS

- Complete a randomized control trial evaluating OXYMIND for the treatment of NS in patients with SSD.
- Identify potential mechanism of action to optimize therapeutic effects.

LONG-TERM GOALS

- Establish OXYMIND as a validated and effective treatment option for NS in patients with SSD in different medical centers and countries.